Pharma firm Jubilant Organosys today said it has joined hands with the University of Alabama at Birmingham and Southern Research Institute to benefit from their collective innovation and enabling technologies.
"We are happy to join hands with UAB and Southern Research Institute, known for its strengths in the areas of oncology, metabolic disease and infectious diseases," Jubilant Organosys Chairman and Managing Director S Bhartia said in a filing to the Bombay Stock Exchange..
The agreement includes selecting the most promising biological targets discovered by biomedical researchers at UAB, Southern Research and Jubilant, developing new drugs around these targets through work performed at UAB and Southern Research, and Jubilant in India.
"UAB has tremendous strength in research that identifies the targets – usually proteins – that contribute to the disease process, whether it is cancer or diabetes," UAB Vice President for Research and Economic Development said.
The UAB Research Foundation plays a significant role in commercialising research, to the benefit of local and state economic development and Southern Research Institute is a nonprofit scientific research organisation that conducts pre-clinical drug discovery and development.
